20-F: Argenx Unveils 2023 Equity Incentive Plan to Align Employee Interests with Long-Term Growth

Argenx introduces a new equity incentive plan in 2023, offering stock options and restricted stock units (RSUs) to key personnel to foster long-term commitment and align their interests with the company's success.

Summary

• Argenx has established an Equity Incentive Plan in 2023 to attract, retain, and motivate key personnel, including employees, consultants, advisors, and directors.
• The plan offers two types of equity incentives: stock options, which allow participants to purchase shares at a predetermined price, and RSUs, which grant participants the right to receive shares at a future date.
• Eligibility for participation is determined by the board of directors, with grants subject to continued performance and commitment to Argenx.
• Vesting schedules are in place to promote long-term commitment, with stock options vesting over 36 months and RSUs over 48 months.
• Accelerated vesting occurs in the event of dissolution, sale of assets, or a change of control.
• The plan outlines procedures for exercising stock options and settling RSUs, including considerations for insider trading policies and tax obligations.
• Argenx reserves the right to amend the plan and deviate from its terms for specific grants, ensuring flexibility and compliance with local tax regimes.
• Special rules apply to key persons taxed in Belgium, the United States, Canada and Switzerland, including acceptance deadlines, exercisability restrictions, and holding periods.
• The plan is governed by the laws of the Netherlands.

Sentiment

Score: 7

Explanation: The document is factual and positive, outlining a plan to incentivize employees and align their interests with the company's success. It does not contain any negative or concerning information.

Positives

• The plan is designed to align the interests of key personnel with those of Argenx's stakeholders.
• It rewards long-term value creation and promotes long-term commitment to the company.
• The plan offers flexibility in equity incentive packages, allowing for different compositions of stock options and RSUs.
• Accelerated vesting provides protection for participants in the event of significant corporate events.

Negatives

• Unvested stock options and RSUs terminate without compensation if an employee leaves Argenx, except in cases of death or permanent disability, or if the board decides otherwise.
• Participants are fully liable for any income, wage taxes, or social security contributions related to the equity incentives.
• There is no guarantee that there will be a buyer for shares at the asking price or at all.
• Members of the board of directors are not allowed to exercise stock options within the first 3 years following the date of grant of such stock options.

Risks

• Violation of the insider trading policy may lead to dismissal and even criminal prosecution.
• There is no guarantee that there will be a buyer for shares at the asking price or at all.
• argenx will not be liable for any malfunction in a third-party online equity portal.
• argenx makes no guarantee that the equity incentives comply with or are exempt from Section 409A of the Code and argenx shall have no liability for the failure of the terms of this plan or any equity incentives to comply with or be exempt from the provisions of Section 409A of the Code.

Future Outlook

The plan aims to incentivize key personnel to contribute to Argenx's sustainable long-term success and align their interests with those of other stakeholders.

Management Comments

• Our mission is to transform patients lives by providing them with life-changing medicines which build on scientific breakthroughs in immunology.
• At argenx, we have a pay-for-performance culture, of which long term equity incentive grants are a key component.

Industry Context

Equity incentive plans are a common practice in the biopharmaceutical industry to attract and retain talent, particularly in companies focused on long-term research and development.

Comparison to Industry Standards

• The vesting schedules (36 months for stock options, 48 months for RSUs) are fairly standard compared to other companies in the biotech industry.
• The plan's flexibility in offering different compositions of stock options and RSUs is a feature seen in some, but not all, equity compensation plans.
• The accelerated vesting provisions upon a change of control are also common in executive compensation packages.

Stakeholder Impact

• Shareholders: The plan aims to increase shareholder value by aligning employee incentives with long-term company performance.
• Employees: The plan provides an opportunity for employees to become co-owners of the business and share in its success.
• Customers: By incentivizing employees, the plan aims to improve the development and delivery of life-changing medicines to patients.

Next Steps

• The board of directors will determine which key persons are eligible for participating in this plan.
• The board of directors maintains an equity incentive grant allocation scheme detailing the criteria for determining the number of equity incentives granted to you during the course of your engagement.
• The company may choose to offer you the choice of different compositions of your equity incentive package.
• The board of directors requires an authorization from our general meeting of shareholders to be able to grant equity incentives to you.
• argenx will settle vested RSUs by issuing shares to you within 10 business days after the vesting date of such RSUs.

Key Dates

Keywords

equity incentive plan, stock options, restricted stock units, RSUs, vesting, argenx, compensation, shareholders, board of directors, key personnel